Tuesday, 07 Apr 2020

Biologic/Novel Rx

Datesort ascending Type Title Save
31 Mar 2020 Social RT @Drugscom: Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque…
31 Mar 2020 Social RT @Janetbirdope: Should Rheum & Derm pts stop biological during #Covid_19? Likely not as a flare may put pts at risk of seeking medical at…
26 Mar 2020 Slide of the day Stages of COVID-19
25 Mar 2020 News ACR Infusion Guidance During COVID-19 Crisis
25 Mar 2020 Social American Academy of Dermatology issues guidance on COVID - 1) Do NOT stop biologic therapy without calling your Dr. 2) Especially for those without COVID symptoms or a (+)test; 3) if you have a proven COVID infection, stop the biologic https://t.co/ppVNUcdZm4
23 Mar 2020 Social Considerations on how to do biologic infusions in Rheum patients - "Infusions in the time of corona" by Dr. Eric Ruderman.
22 Mar 2020 ACR Video Rheumnow PSA 1 - Managing Your Arthritis Medicines
20 Mar 2020 News Infusions in the Time of Coronavirus
16 Mar 2020 Social Follow current COVID19 precautions. Most of our Rheum Dz pts are safe on current therapies. I would advise tp continue biologics/immunosuppressives to maintain dz control. Only stop if the pt is hospitalized or has a high fever >102F (and call you/MD for further instruction)
12 Mar 2020 News Earlier Anakinra Initiation Warranted in Still's Disease
12 Mar 2020 News Switching Biologics in JIA
07 Mar 2020 Social RT @DrAiLynTan: Tocilizumab (Actemra) has been approved by the Chinese government to treat severe #coronavirus symptoms https://t.co/ETE…
06 Mar 2020 Social Small phase II pilot trial of Tocilizumab in JIA (n=22) associated uveitis failed to show efficacy - 34% (7/21) responded to treatment (p=0·11). https://t.co/2EoCfLcVOA
02 Mar 2020 Social U.S. FDA Accepts Regulatory Submission for Tanezumab, an NGF inhibitor, for the Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis https://t.co/9NsESTnn4S
20 Feb 2020 News Tofacitinib Effective in Refractory Still's Disease
19 Feb 2020 ACR Video QD Clinic - Dosing RTX and REM
17 Feb 2020 ACR Video Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD
15 Feb 2020 Social RT @RheumNow: Fenebrutinib, a BTK inhibitor, is better that placebo, but not ADA when given in a phase 2 trial. Drs. Fleischman/Genovese…
15 Feb 2020 Social RT @Janetbirdope: Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab b…
15 Feb 2020 Social Finch 3 trial in MTX naive pts shows that mono Rx FIL 200=MTX mono for ACR20 but FIL200 superior for ACR50/70. 200mg works faster with more big responders early. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/msgB6DS5cl